Sacituzumab Govitecan for Triple Negative Breast Cancer
This study is testing sacituzumab govitecan, alone or with pembrolizumab, for people with localized triple negative breast cancer (TNBC). TNBC is a type of breast cancer that doesn't have certain receptors (ER, PR, HER2). Sacituzumab govitecan is an antibody-drug conjugate, meaning it delivers a drug directly to cancer cells. Pembrolizumab is an immunotherapy that helps your immune system fight cancer. The study aims to see how many people have a complete response to treatment. You may be able to join if you are at least 18 years old and have newly diagnosed invasive breast cancer. The study is currently enrolling about 50 participants.
- Study design
- This is a Phase II clinical trial, which tests the safety and effectiveness of sacituzumab govitecan. It is a multi-arm study, meaning some participants will receive sacituzumab govitecan alone, and others will receive it with pembrolizumab.
- What's involved
- Eligible participants will receive sacituzumab govitecan for up to 12 weeks. This may be followed by standard chemotherapy, as decided by your doctor. You will have screening, study treatment, evaluations, and follow-up visits.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, pathological complete response, is measured at 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04230109
Sacituzumab Govitecan In TNBC
Recruiting
PHASE2Ages 18+InterventionalTreatmentMassachusetts General HospitalInvestigator-initiated
~239 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:Sacituzumab GovitecanPembrolizumab
At a glance
Recruiting sites
4 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pathological complete response(pCR) rate with sacituzumab govitecan
Measured over 12 Weeks
Conditions
Where it's being run
5 sites across 1 statesMassachusetts5
Study leadership
- Laura Spring, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Female or male patients ≥ 18 years of age.
Histologically confirmed diagnosis of invasive breast cancer, previously untreated.
Pre-and postmenopausal women are eligible to participate if not pregnant, not breastfeeding, and at least one of the following conditions applies:
Not a woman of childbearing potential (WOCBP) OR
A WOCBP who agrees to use effective contraceptive measures that have a failure rate of less than 1% per year from the initiation of treatment through at least 6 months b. after the last dose of study treatment. WOCBP must agree to 1 of the following contraceptive methods:
Complete abstinence from intercourse of reproductive potential, or
Consistent and correct use of 1 of the following methods of birth control:
Nonhormonal intrauterine device (IUD); Hormonal IUD in conjunction with a barrier method; Female sterilization (have had surgical bilateral oophorectomy with or; without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment; Vasectomy in the male partner (upon medical assessment of surgical success)
Male patients with female partners of childbearing potential must practice
Complete abstinence from intercourse of reproductive potential
Have a surgically successful vasectomy upon medical assessment, or
Use condoms plus partner use of a contraceptive method with a failure rate of \<1% per year during treatment and until 3 months after last dose of study drug.
ECOG performance status = 0, 1 (Karnofsky ≥60%, see Appendix A)
Ability to understand and the willingness to sign a written informed consent form (ICF). Patient has signed the ICF prior to any screening procedures being performed and is able to comply with protocol requirements, including research biopsy.
Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:
Absolute neutrophil count (ANC) ≥ 1,500 per mm3
Platelets ≥ 100,000 per mm3
Hemoglobin ≥9.0 g/dL
PT-INR ≤1.5 x institutional ULN unless participant is receiving anticoagulant therapy as long as PT or aPPT is within therapeutic range of intended use of anticoagulants (for patients receiving pembrolizumab only).
Serum creatinine \<1.5 mg/dL or creatinine clearance ≥50 mL/min (via the Cockcroft-Gault formula) for participants with creatinine levels above institutional upper limit of normal (ULN)
Adequate hepatic function (bilirubin ≤ 1.5 ULN, AST and ALT ≤ 2.5 X ULN and serum albumin \> 3 g/dL).
Exclusion
Participants currently receiving systemic therapy for any malignancy or having received systemic therapy for a malignancy in the preceding 3 years. (Concurrent endocrine therapy allowed in the adjuvant setting. Concurrent GnRH agonists allowed in any setting. Concurrent CDK4/6 inhibitor not allowed in any setting.)
Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:
History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry.
History of cardiac failure, known cardiomyopathy (LVEF \< 50%; new LVEF assessment is not specifically required for this trial), significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following: ---Known risk to prolong the QT interval or induce Torsade's de Pointes.; Uncorrected hypomagnesemia or hypokalemia; Systolic Blood Pressure (SBP) \>160 mmHg or \<90 mmHg. Higher blood pressure is permissible per discretion of treating physician; Bradycardia (heart rate \<50 at rest), by ECG or pulse; On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF \>470 screening ECG
Pregnant or breast-feeding women are excluded from this study because the safety of study medications is not established.
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to enrollment are eligible for this trial. Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to registration. Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Participants who are not good candidates for the study (as per investigator judgement)
History of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to sacituzumab govitecan.
What this trial measures
- Pathological complete response(pCR) rate with sacituzumab govitecan12 Weeks
pCR is defined as no residual invasive carcinoma in the breast and in the lymph node. The two-sided 95% CIs for pCR rate will be calculated.